Ambrx和新碼生物達成第二項合作, 開發和商業化Ambrx的抗體偶聯藥物


Ambrx and NovoCodex form Second Collaboration to Develop and Commercialize Ambrx's Antibody Drug Conjugates

SAN DIEGO and SHANGHAI, October 22, 2019 /PRNewswire/ -- Ambrx and NovoCodex Biopharmaceuticals Ltd., (NovoCodex), a majority owned company of Zhejiang Medicine Co Ltd., today announced that they have formed a second collaboration to develop and commercialize Ambrx's internally developed site-specific antibody drug conjugates (ADCs).  Under the agreement, Ambrx and NovoCodex will join forces to continue the development of ARX305, an Ambrx enabled ADC for the treatment of CD70 positive cancers.


美通社(PR Newswire )/圣地亞哥和上海,2019年10月22日- Ambrx和浙江醫藥股份有限公司的控股子公司浙江新碼生物醫藥有限公司(簡稱“新碼生物”)今天通告,他們已達成第二項合作,開發和商業化Ambrx自主開發的定點修飾的抗體偶聯藥物(ADCs)。 根據協議,Ambrx和新碼生物將聯合繼續開發ARX305,即一種由Ambrx開發的用于治療CD70陽性腫瘤的ADC。


Under the terms of the agreement, NovoCodex is responsible for developing and commercializing ARX305 in China while Ambrx is responsible for developing and commercializing ARX305 outside of China. NovoCodex will fund global development activities to the end of Phase 1 clinical trials and pay Ambrx an undisclosed upfront payment, development milestones, and a double-digit royalty on product sales in China. NovoCodex is also eligible to share in undisclosed portion of ARX305 product sales outside of China.




"We are excited to initiate our second collaboration with NovoCodex following our successful collaboration with ARX788, which is currently in Phase 1 clinical trials for HER2 positive breast and gastric cancers. ARX305 is a natural extension to the first collaboration with the inclusion of another Ambrx enabled ADC that is intended to treat CD70 positive cancers such as Renal Cell Carcinoma and Multiple Myeloma. Further, we continue to align ourselves with China's leading pharmaceutical companies" said Feng Tian, Ph.D., Chief Executive Officer of Ambrx. "ARX305, which is expected to start Phase 1 clinical trials in early 2021, allows Ambrx to expand its ADC pipeline into multiple cancer types while gaining access to the China market through our partnership with NovoCodex."


“繼ARX788的成功合作之后,我們很高興與新碼生物展開第二次合作。目前,ARX788正在進行HER2陽性乳腺癌和胃癌的I期臨床試驗。ARX305是首次合作的自然延伸,包含另一種Ambrx開發的ADC,該ADC旨在治療CD70陽性腫瘤,如腎細胞癌和多發性骨髓瘤。此外,我們繼續與中國領先的制藥公司保持合作。” Ambrx首席執行官田豐博士說。“ARX305有望在2021年初啟動I期臨床試驗,它將使Ambrx的ADC管線擴展到多種腫瘤類型,同時通過與新碼生物的合作進入中國市場。”


Chunbo Li, Chairman of Zhejiang Medicine, commented, "The smooth progress of our first ZMC-Ambrx collaborated ADC project, ARX788, proves that Ambrx’ technology is one of the best methods to make an ADC drug.  The new alliance with Ambrx on ARX305 will strengthen our leading position on ADC research, and hopefully will bring new treatment to related cancer patients.”




About Ambrx




Ambrx Inc. is a clinical stage biopharmaceutical company using an expanded genetic code to create first- and/or best-in-class biotherapeutics, including antibody drug conjugates (ADC), immunomodulating proteins, bispecific antibodies and other therapeutic proteins with improved pharmacologic properties.  Leveraging the Ambrx proprietary technology platforms, Ambrx has collaborations with Bristol-Myers Squibb, Astellas, BeiGene, Elanco and ZMC, with drug products generated using Ambrx technology in different stages of clinical trials. Ambrx is advancing a robust portfolio of product candidates that are optimized for efficacy, safety and ease of use in multiple therapeutic areas. For additional information, visit www.ambrx.com 


Ambrx是一家臨床階段的生物制藥公司,使用擴展的遺傳密碼創建一流和/或最佳的生物治療藥物,包括抗體偶聯藥物(ADC)、免疫調節蛋白、雙特異性抗體,和其他具有改善藥理特性的治療性蛋白質。 利用Ambrx專有技術平臺,Ambrx與Bristol-Myers Squibb、Astellas、BaiGene、Elanco、ZMC合作,并在不同的臨床試驗階段使用Ambrx技術生產藥品。 Ambrx正在推進候選產品穩健組合,針對多治療領域的功效、安全性和易用性進行了優化。 有關更多信息,請訪問www.ambrx.com


About ARX305



CD70 is highly expressed in multiple solid and liquid tumors such as Renal Cell Carcinoma, Multiple Myeloma, Non-Hodgkin’s Lymphoma, AML, and etc. ARX305 is a best-in-class anti-CD70 ADC that was precision-engineered using Ambrx proprietary antibody and clinically validated drug payload. Strong in vitro and in vivo efficacy have been demonstrated in multiple tumor cells and models.  It is expected to deliver a direct killing to CD70-overexpressing tumor and improvement of the immune suppression in the tumor microenvironment.


CD70在多種實體瘤和液體瘤中高度表達,如腎細胞癌、多發性骨髓瘤、非霍奇金淋巴瘤、AML等。ARX305采用Ambrx自主知識產權的抗體和經臨床驗證的毒素,是一個經過精密設計的最佳抗CD70 ADC, 在多種腫瘤細胞和模型中已證明強大的體外和體內功效,有望直接殺死過表達CD70的腫瘤,并改善腫瘤微環境中的免疫抑制作用。


About NovoCodex




NovoCodex is a majority owned company of Zhejiang Medicine Co., Ltd. (stock code: SH.600216), mainly committed to the research and development of biological products. The company's laboratory has experience and capabilities in genetic engineering, cell culture, toxin synthesis, conjugation, formulation & filling, preclinical study and clinical study. ARX788 project has been successfully advanced to the later stage of Phase 1 clinical trial in China. For additional information, visit http://www.novocodex.cn/




维京掠宝送彩金 欧冠篮球比分直播 安徽麻将教学 2020cba赛程表 中国足球彩票比分直播竞彩网 老11选5 3d开奖结果乐彩网 竞彩足球比分动画直播 nba比分直播 训营 黑龙江6+1 江苏十一选五今天结 黔友贵州麻将透视修改器 河南杠次麻将单机 北京麻将胡法大全 pk10牛牛 江苏江苏11选5走 微信登录欢乐麻将